Cited by 262Isoquinoline Alkaloid SynthesisCancer therapeutics and mechanismsBioactive Compounds and Antitumor Agents

The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

Erba, E, Bergamaschi, D, Bassano, L, Damia, G, Ronzoni, S, Faircloth, G.T, D'Incalci, M·2001·European Journal of Cancer

Open this paper in CoChat — free account

Abstract

The mode of action of Ecteinascidin-743 (ET-743), a marine tetrahydroisoquinoline alkaloid isolated from Ecteinascidia turbinata, which has shown very potent antitumour activity in preclinical systems and encouraging results in Phase I clinical trials was investigated at a cellular level. Both SW620 and LoVo human intestinal carcinoma cell lines exposed for 1 h to ET-743 progress through S phase more slowly than control cells and then accumulate in the G2M phase. The sensitivity to ET-743 of G1 synchronised cells was much higher than that of cells synchronised in S phase and even higher than that of cells synchronised in G2M. ET-743 concentrations up to four times higher than the IC(50) value caused no detectable DNA breaks or DNA-protein cross-links as assessed by alkaline elution techniques. ET-743 induced a significant increase in p53 levels in cell lines expressing wild-type (wt) (p53). However, the p53 status does not appear to be related to the ET-743 cytotoxic activity as demonstrated by comparing the drug sensitivity in p53 (-/-) or (+/+) mouse embryo fibroblasts and in A2780 ovarian cancer cells or the A2780/CX3 sub-line transfected with a dominant-negative mutant TP53. The cytotoxic potency of ET-743 was comparatively evaluated in CHO cell lines proficient or deficient in nucleotide excision repair (NER), and it was found that ET-743 was approximately 7-8 times less active in ERCC3/XPB and ERCC1-deficient cells than control cells. The findings that G1 phase cells are hypersensitive and that NER-deficient cells are resistant to ET-743 indicate that the mode of action of ET-743 is unique and different from that of other DNA-interacting drugs.

Integrity signals

Registry

Crossref · 10.1016/s0959-8049(00)00357-9

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
RINEHART, K. L. J., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F.-R., Li, L. H., & Martin, D. G. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a007 · Cited by 493
DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia turbinata
Pommier, Y. G., Kohlhagen, G., Bailly, C., Waring, M. J., Mazumder, A., & Kohn, K. W. (1996) · Biochemistry · doi:10.1021/bi960306b · Cited by 304
Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line
Drummond, J. T., Anthoney, A., Brown, R. E., & Modrich, P. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277
Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail‐Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 219
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
Jin, S. V., Gorfajn, B., Faircloth, G. T., & Scotto, K. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6775 · Cited by 206
Self-citation
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G. T., D’Incalci, M., & Mantovani, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6780 · Cited by 195
Self-citation
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
Martinez, E. J., Owa, T., Schreiber, S. L., & Corey, E. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3496 · Cited by 170
The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove.
Rice, J. A., Crothers, D. M., Pinto, A. L., & Lippard, S. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4158 · Cited by 168
In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
Izbicka, E., Lawrence, R., Raymond, É., Eckhardt, G., Faircloth, G. T., Jimeno, J. M., Clark, G. M., & VonHoff, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008224322396 · Cited by 137
Self-citation

Flagged first, then by citations

Show all 28 references

2 of the 28 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

Guan, 1993, Molecular and crystal structures of ecteinascidins, J. Biomol. Struct. Dyn., 10, 793
Rayan, 1999, A phase I and pharmacokinetic trial of ecteinacidin-743 (ET-743) administered as a 72 hour continuous infusion, Proc. ASCO, 18, 188a
Cvitkovic, 1999, Final results of phase 1 study of ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients (pts), Proc. ASCO, 18, 180a
Rosing, 1999, Pharmacokinetics (PK) of Ecteinascidin-743 (ET-743) in three different phase I trials, Proc. Am. Assoc. Cancer Res., 40, 81
Jimeno, 1999, Pharmacokinetics (PK)/pharmacodynamic (PD) relationships in patients (PT) treated with Ecteinascidin-743 (ET-743) given as 24 hours (h) continuous infusion (CI), Proc. ASCO, 18, 193a

Sorted by citations

Items 201–262 of 262

Modes of cell death induced by tetrahydroisoquinoline-based analogs in MDA-MB-231 breast and A549 lung cancer cell lines
Nel, M., Joubert, A. M., Döhle, W., Potter, B. V. L., & Mercier, A. E. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s152718 · Cited by 8
Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells
Manda, K., Präkelt, T., Schröder, T., Kriesen, S., & Hildebrandt, G. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00852-x · Cited by 8
Novel Approaches to Treatment of Leiomyosarcomas
Collins, I. M., & Thomas, D. M. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0173-0 · Cited by 8
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
Neia, C. P., Cavalloni, G., Soster, M., Gammaitoni, L., Marchiò, S., Sassi, F. P., Trusolino, L., Bertotti, A., Médico, E., Capussotti, L., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-918 · Cited by 8
Exploring the global animal biodiversity in the search for new drugs -marine invertebrates
Mans, D. R. A. (2016) · Journal of Translational Science · doi:10.15761/jts.1000136 · Cited by 8
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Souid, S., Aissaoui, D., Srairi‐Abid, N., & Essafi‐Benkhadir, K. (2020) · Current Drug Targets · doi:10.2174/1389450121666200128161733 · Cited by 7
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies
Machiels, J. P., Staddon, A. P., Herremans, C., Keung, C., Bernard, A., Phelps, C. E., Khokhar, N. Z., Knoblauch, R. E., Parekh, T. V., Dirix, L. Y., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2554-1 · Cited by 7
Bioactive substances with anti-neoplastic efficacy from marine invertebrates:Bryozoa,Mollusca,EchinodermataandUrochordata
Šíma, P. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i11.362 · Cited by 7
Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin
Guirouilh‐Barbat, J., Zhang, Y., & Pommier, Y. G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0320 · Cited by 7
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
Glinkina, K., Némati, F., Teunisse, A. F. A. S., Gelmi, M. C., Etienne, V., Kuipers, M. J., Alsafadi, S., Jager, M. J., Decaudin, D., & Jochemsen, A. G. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.13.14 · Cited by 6
Past, Present and Future of Therapies in Pediatric Sarcomas
Hingorani, P., & Kolb, E. A. (2010) · Future Oncology · doi:10.2217/fon.10.19 · Cited by 6
Produtos Naturais em Fase Avançada de Testes Clínicos no Tratamento contra o Câncer
Souza, M. V. N. D., Pinheiro, A., Ferreira, M. L., Gonçalves, R. S. B., & Lima, C. H. D. C. (2007) · Revista Fitos · doi:10.32712/2446-4775.2007.72 · Cited by 6
Natural small-molecules reverse Xeroderma Pigmentosum Complementation Group C (XPC) deficient-mediated drug-resistance in renal cell carcinoma
Chen, R., Lo, H. H., Yang, C., Law, B. Y. K., Chen, X., Lam, C. C. I., Ho, C., Cheong, H. L., Li, Q., Zhong, C., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155310 · Cited by 5
In Silico Screening of Natural Metabolites as Inhibitors of Biosynthesis and Transport of Enterobactin
(2022) · Biointerface Research in Applied Chemistry · doi:10.33263/briac132.125 · Cited by 5
Ecteinascidin-743
Held-Warmkessel, J. (2003) · Clinical journal of oncology nursing · doi:10.1188/03.cjon.313-319 · Cited by 5
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies
von Mehren, M., Bookman, M. A., Meropol, N. J., Weiner, L. M., Sherman, E. J., Li, J., Knoblauch, R. E., Parekh, T. V., & Cohen, R. B. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2705-z · Cited by 5
Trabectedin is a promising antitumour agent for synovial sarcoma
Yasui, H., Imura, Y., Outani, H., Hamada, K., Nakai, T., Yamada, S., Takenaka, S., Sasagawa, S., Araki, N., Itoh, K., et al. (2016) · Journal of Chemotherapy · doi:10.1080/1120009x.2015.1133013 · Cited by 5
Effect of Continuous Care Model on Body Image Among Breast Cancer Patients Undergoing Chemotherapy: A Clinical Trial
Elahi, N., Imanian, M., Zarea, K., Ahmadzadeh, A., & Jahromi, M. K. (2017) · International Journal of Cancer Management · doi:10.5812/ijcm.8104 · Cited by 5
Marine natural products: the new generation of pharmacotherapeutics
Goel, R., Mahendru, B., & Saini, T. (2021) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20212389 · Cited by 4
Molecular basis of differentiation therapy for soft tissue sarcomas.
Luther, G. A., Rames, R., Wagner, E. R., Zhu, G., Luo, Q., Bi, Y., Kim, S. H., Gao, J., Huang, E., Yang, K., et al. (2010) · PubMed · Cited by 5
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma
Spriano, F., Chung, E. Y., Panini, N., Cascione, L., Rinaldi, A., Erba, E., Stathis, A., D’Incalci, M., Bertoni, F., & Gatta, R. P. (2018) · British Journal of Haematology · doi:10.1111/bjh.15212 · Cited by 5
Self-citation
DNA-binding agents
Nieto, Y. L. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22008-7 · Cited by 5
Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas
Poitureau, S., Deley, M. L., Brahmi, M., Bompas, E., Kurtz, J., Nannini, S., Perrin, C., Lebellec, L., Ryckewaert, T., Ould‐Ammar, R., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71131 · Cited by 4
Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma
Cioffi, A., & Italiano, A. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.636353 · Cited by 4
Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies
Pasetto, L. M., Basso, U., & Brandes, A. A. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.2.167 · Cited by 4
Magnetic resonance imaging of mouse Ehrlich carcinoma growth inhibition by thiacarpine, an analogue of cytotoxic marine alkaloid polycarpine
Агафонова, И. Г., Radchenko, O. S., Novikov, V. L., Aminin, D. L., & Stonik, V. A. (2008) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2008.01.014 · Cited by 4
Trabectedin
&NA; (2003) · Drugs in R&D · doi:10.2165/00126839-200304010-00016 · Cited by 4
Trabectedin (ET-743) from Marine Tunicate for Cancer Treatment
Atmaca, H., & Bozkurt, E. (2014) · Springer eBooks · doi:10.1007/978-3-319-07145-9_19 · Cited by 3
Marine Organisms and Their Prospective Use in Therapy of Human Diseases
Ebada, S. S., & Proksch, P. (2011) · Springer eBooks · doi:10.1007/978-3-642-19382-8_7 · Cited by 3
Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study
Ön, S., Köksal, B., Arık, Z., Caner, B., Uzundal, D. E., Yazıcı, O., Benli, B. A., Mocan, E. E., Cangür, C., Güç, Z. G., et al. (2024) · Current Oncology · doi:10.3390/curroncol31110502 · Cited by 3
A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma
Reuben, D. Y. (2021) · Journal of Medical Cases · doi:10.14740/jmc3655 · Cited by 3
Medical Treatment of Gastrointestinal Stromal Tumors: State of the Art and Future Perspectives
Apice, G., Milano, A., Bruni, G. S., Iaffaioli, R. V., & Caponigro, F. (2006) · Reviews on Recent Clinical Trials · doi:10.2174/157488706775246175 · Cited by 3
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
Pantano, F., Simonetti, S., Iuliani, M., Navarro, M. J. G., Cuevas, C., Avilés, P., Cavaliere, S., Napolitano, A., Cortellini, A., Mazzocca, A., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03143-9 · Cited by 2
Can the use of aquatic non-native species across Europe mitigate their environmental impact?
Dobrzycka-Krahel, A., & Román‐Hidalgo, C. (2025) · Environmental Impact Assessment Review · doi:10.1016/j.eiar.2025.107932 · Cited by 2
Synthesis of tunichrome Sp-1
Pullar, M. A., Barker, D. L. A., & Copp, B. R. (2015) · Tetrahedron Letters · doi:10.1016/j.tetlet.2015.08.047 · Cited by 2
Non-Pharmaceutical Interventions in Cancer Therapy
Tyagi, V., Tanwar, N., Kumar, N., Phogat, N., Kumar, P., & Kumar, V. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947268161240404084729 · Cited by 2
Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature
Karbhari, N., & Khagi, S. (2024) · Onco · doi:10.3390/onco4040026 · Cited by 2
Design, synthesis, and biological evaluation of simplified tetrahydroisoquinoline analogs
Yang, Y., Gao, Y., Chen, S., Guo, J., & Hu, Y. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300453 · Cited by 2
Trabectedin: Novel Insights in the Treatment of Advanced Sarcoma
Lopez, J. P., Gajdos, C., & ELIAS, A. D. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0387-z · Cited by 2
Science and serendipity in cancer research
Smyth, J. F. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00379-8 · Cited by 2
Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib
Kang, B., Lee, S.-J., Seol, K. H., Jeong, Y. Y., Choi, J., Choi, B.-H., Ryu, J. M., & Choi, Y. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072921 · Cited by 1
In silico screening of biosynthetic traits driving biotechnological utility of coagulase negative, food-associated Staphylococcus Strains
Babalola, O. O., Yousuf, S., Adefiranye, O. O., Chukwuneme, C. F., Ojuederie, O. B., & Adeniji, A. A. (2026) · The Microbe · doi:10.1016/j.microb.2026.100732 · Cited by 1
New drugs in the management of sarcoma
Moore, M. A., & Desai, J. (2010) · Cancer Forum · Cited by 1
Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation
Greco, F., Piacentini, P., Remo, A., Bonetti, A. V., & Ferrandina, G. (2016) · Cancer Breaking News · doi:10.19156/cbn.2016.0008 · Cited by 1
Anticancer activity of natural compounds from marine animals
Banik, B. K., & Das, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99710-2.00012-3 · Cited by 2
The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma
Gäbele, E., Gigante, I., Pastore, M., Cigliano, A., Galleri, G., Bauer, T., Pizzuto, E., Mancarella, S., Müller, M., Marra, F., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189085 · Cited by 1
Effect of supercritical and aqueous-alcoholic extracts from Halocynthia Aurantium on gametes, zygotes, and embryos of sea urchin
Drozdov, A. L., Chizhova, T., Чудновский, В. М., Yusupov, V. I., Pokrovskiy, O. I., Паренаго, О. О., Германовна, Б. Н., Isai, S. V., & Bagratashvili, V. N. (2009) · Russian Journal of Physical Chemistry B · doi:10.1134/s199079310908003x · Cited by 1
NATURAL REMEDIES WITH POTENTIAL ANTI-CANCER ACTIVITY AND ROLE OF PLANT TISSUE CULTURE IN DEVELOPMENT OF THOSE REMEDIES: A REVIEW
Pandey, A., & Tripathi, S. (2014) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.050206 · Cited by 1
Surgical Management of Skin Necrosis due to Trabectedine Extravasation : Two Cases Report
Sugihara, S., Ikeda, K., Yamasaki, O., Morizane, S., Shimoe, K., & Nakamura, K. (2021) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.83.417 · Cited by 1
Total synthesis of selected tyrosine‐derived alkaloids: A comparative analysis of tyrosine‐based chiral pool vs other synthetic approaches
Banerjee, A., Chatterjee, I., & Panda, G. (2022) · ChemistrySelect · doi:10.1002/slct.202202750 · Cited by 1
Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Signal Transduction Pathways Related to Tumor Growth
Miao, X., Shen, S., Koch, G., Wang, X., Li, J., Shen, X., Qu, J., Straubinger, R. M., & Jusko, W. J. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.030 · Cited by 1
Rationale for drug combinations
Smyth, J. F. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00452-0 · Cited by 1
Tratamiento quimioterapéutico de los sarcomas de partes blandas
Thornton, K. A. (2008) · Clínicas quirúrgicas de Norteamérica
Ascidians (Tunicates)–2
Kornprobst, J. (2014) · Wiley eBooks · doi:10.1002/9783527335855.marprod282
Role of New Chemotherapy Agents in Soft Tissue Sarcoma
von Mehren, M. (2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0012
Community Structure of Ascidian in Mike’s Point Bunaken Waters, Manado City, North Sulawesi Province
Opa, S. L., Sumilat, D. A., Pratasik, S. B., Wagey, B. T., Mamangkey, N. G. F., Ginting, E. L., & Ompi, M. (2020) · JURNAL ILMIAH PLATAX · doi:10.35800/jip.8.1.2020.27827
Transaminase and Norcoclaurine Synthase One‐Pot Cascades Towards (1 S )‐Tetrahydroisoquinolines
Zhao, J., Ni, Y., Wang, Y., Ward, J. M., Jeffries, J. W. E., & Hailes, H. C. (2026) · ChemBioChem · doi:10.1002/cbic.202500823
Mécanisme d'action de nouveaux agents alkylants ciblant l'ADN ou les protéines
Lenglet, G. (2010) · doi:10.70675/f7a50760z74ccz45b9zbe6fze031c90c11b3
DNA double-strand break formation and signalling in response to transcription-blocking topoisomerase I complexes
Cristini, A. (2015) · theses.fr (ABES) · doi:10.70675/89719cadza51cz4509zbd9fz3da99c280491
Etude des mécanismes impliqués dans l'hépato-toxicité des médicaments anti-cancéreux : exemples de la trabectedine et des inhibiteurs de tyrosine kinases
Maillard, M. (2021) · theses.fr (ABES) · doi:10.70675/fcc755aez86d6z4e97z83dez91ff7531a2df
In silico tools and computational biology in natural product research
Majumdar, D., Ghosh, A., Shaw, S., Nandi, S., & Samadder, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-48509-1.00006-9
Marine Natural Products with Novel Mechanisms of Action: From Disrupting Gene Expression to Reshaping the Tumor Microenvironment and Beyond
Huang, J., Liu, J., Chong, C., Guo, Y., & Jin, X. (2026) · Chemistry · doi:10.3390/chemistry8100145

Authors: Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., & D'Incalci, M.
Affiliations: Mario Negri Institute for Pharmacological Research (IT)
Rayonix (United States) (US)
Corresponding author: Erba, E
ORCID: Bergamaschi, D
Damia, G
Ronzoni, S
Venue: European Journal of Cancer
Publisher: Elsevier BV
Published: 2001-01
Volume: 37
Issue: 1
Pages: 97-105
ISSN: 0959-8049 (ISSN-L)
DOI: 10.1016/s0959-8049(00)00357-9
OpenAlex: W2153737617
Cited by: 262
References: 28
Citations by year: 2026: 4 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 8 · 2021: 7 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 21 · 2014: 19 · 2013: 9 · 2012: 4
FWCI: 6.19
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Journal of Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Cancer Research Institute
Associazione Italiana per la Ricerca sul Cancro
Topics: Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords: trabectedin, Ecteinascidia turbinata, cell cycle arrest, p53, nucleotide excision repair, ERCC1, DNA damage, DNA-protein crosslinks, ovarian cancer cell lines, drug resistance
MeSH terms: Trabectedin, Cell Cycle, Cell Division, Colonic Neoplasms, Dioxoles, DNA Damage, DNA, Neoplasm, Drug Screening Assays, Antitumor, Humans, Isoquinolines, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Cyclins, Antineoplastic Agents, Alkylating, Tetrahydroisoquinolines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks